Sales & Marketing News | pharmaphorum

News

Micrograph showing a small B-cell lymphoma compatible with follicular lymphoma

BeiGene breaks new ground for BTK drugs in blood cancers

BeiGene’s BTK inhibitor Brukinsa has become the first drug in the class to be approved in the US for follicular lymphoma, giving it the broadest label among its rivals.

News

UK Chancellor of the Exchequer Jeremy Hunt

UK Chancellor trumpets £650m AstraZeneca investment

A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.

News

Bayer CEO pulls back from breakup of ‘badly broken’ group

Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati

News

Sandoz gets first FDA OK for denosumab biosimilars

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US

News

FDA clears first OTC glucose biosensor, from Dexcom

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time.

News

Pharma’s Medicare counteroffers are all in, says HHS

On the heels of a setback in pharma’s legal attempts to block Medicare’s new medicine price negotiation powers, the US government has said all drugmakers whose products ar

BeiGene breaks new ground for BTK drugs in blood cancers

UK Chancellor trumpets £650m AstraZeneca investment

Bayer CEO pulls back from breakup of ‘badly broken’ group

Sandoz gets first FDA OK for denosumab biosimilars

FDA clears first OTC glucose biosensor, from Dexcom

Pharma’s Medicare counteroffers are all in, says HHS

J&J's oral IL-23 drug backed for psoriasis in EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks